An Australian research team has developed a large language model (LLM) designed to speed up scientific discovery in molecular property prediction. Lead co-author, PhD candidate Yizhen Zheng, from Mo
An international team including New Zealand researchers found measures of retinal health captured the risk of Alzheimer's disease and related dementias (ADRD) across several domains of known risk fact
The Ministry of Health (MoH) is reviewing the regulation of the New Zealand health workforce and is asking for submissions.
A Moorfields-led team improved the visual acuity (VA) in children with retinal dystrophy caused by a genetic deficiency of AIPL1, using a viral vector to deliver healthy copies of the gene to their re
SpliceBio, a clinical-stage genetic medicine company pioneering protein splicing, has dosed the first patient in the phase 1/2 ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector for the
With waiting lists growing, Drew Jones delves into the factors affecting cataract surgery efficiency
Luxa Biotechnology announced trial results showing substantial improvements in best corrected visual acuity (BCVA) for patients receiving its novel adult retinal pigment epithelial stem cell therapy (
Neurotech Pharmaceuticals announced its Encelto (revakinagene taroretcel-lwey) implant has become the first US Food and Drug Administration (FDA)-approved therapy to slow macular telangiectasia (MacTe
Prof Helen Danesh-Meyer CNZM is the first New Zealander to be appointed president of the Neuro-Ophthalmology Society of Australia (NOSA).
An international team led by New Zealand researchers found patients with type-1 diabetes had stable or improved diabetic retinopathy (DR) after using automated insulin delivery (AID) for at least six months.
New Zealand distributor Toomac Ophthalmic confirms Bausch + Lomb’s 27 March 2025 voluntary recall only concerns the enVista Envy intraocular lens (IOL) in this market.
A University of Sydney literature review found topical cyclosporine (CsA) treatment may be superior to the vehicle, artificial tears (AT) or other topical treatment alternatives for ocular surface dis
